{"search_session":{},"preferences":{"l":"fr","queryLanguage":"fr"},"patentId":"156-245-539-027-892","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"156-245-539-027-892"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11646,"type":"PATENT","title":"UT M. D. Anderson Cancer Center - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":4091,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8312,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately:anderson cancer texas
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 4097
Search Applicants and Owners separately:anderson cancer texas
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 4097
or a salt or prodrug thereof, wherein:\n
R1 is selected from the group consisting of n-hexyl and 2-cyclohexyl ethyl."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["A compound of structural Formula II\n
or a salt or prodrug thereof; wherein:\n
X is selected from the group consisting of C═O, C═S, or SO2;\n
R1 is selected from the group consisting of alkyl containing from 6 to 12 carbon atoms, a polyether, a substituted benzyl and a radical defined by the following structure:\n\n
where n is an integer ranging from 1 to 4; but if R2 is an alkoxy at position 6,then R1 can also be selected from the group consisting of alkyl containing from 1 to 12 carbon atoms;\n
R2 and R2′ vary independently and are selected from the group consisting of hydrogen, aryl, alkyl, cycloalkyl, aralkyl, alkenyl, alkynyl, halogen, an alkoxyl or a hydroxyl;\n
R3 is selected from the group consisting of NR15R16, aryl, a heteroaryl, alkenyl, an alkynyl, an alkoxyl, a cycloalkyl containing from 5 to 10 carbon atoms and containing eventually —CO—, —O—, —S—, —SO—, —SO2—, —CHOH— or —NR12— or one of the radicals defined by the following structure:\n\n
wherein R4 and R5 taken together form a group consisting of a radical cycloalkyl containing from 3 to 10 carbon atoms that are eventually interrupted with one or more hetero atoms or by —CO—, —SO—, —SO2—, —CHOH— or —NR14—;\n
R6 is selected from the group consisting of alkyl containing from 1 to 3 carbon atoms;\n
R7 is selected from the group consisting of alkyl containing from 1 to 3 carbon atoms;\n
R6 and R7 taken together can form a cycloalkyl containing from 3 to 10 carbon atoms and eventually interrupted with one or more hetero atoms or by —CO—, —SO—, —SO2—, —CHOH— or —NR13—;\n
R8 is selected from the group consisting of hydrogen and alkyl from 1 to 3 carbon atoms;\n
R9 and R10 vary independently and are selected from the group consisting of methyl or a hydrogen;\n
R11 is selected from the group consisting of aryl, heteroaryl, or alkyl containing from 1 to 6 carbon atoms, but if R2 is alkoxyl, R11 is heterocycloalkyl;\n
R12 is selected from the group consisting of hydrogen or alkyl containing from 1 to 3 carbon atoms;\n
R13 is selected from the group consisting of hydrogen or alkyl containing from 1 to 3 carbon atoms;\n
R14 represents an alkyl containing from 1 to 3 carbon atoms; and\n
R15 and R16 vary independently and are selected from the group consisting of an alkyl containing 1 to 6 carbon atoms or taken together might form a group consisting of a radical cycloalkyl containing from 3 to 10 carbon atoms that are eventually interrupted with one or more hetero atoms or by —CO—, —SO—, —SO2—, —CHOH— or —NR14—."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["A compound of structural Formula III:\n
or a salt or prodrug thereof, wherein:\n
R1 is selected from the group consisting of n-hexyl and 2-cyclohexyl ethyl;\n
R2 is selected from the group consisting of a hydrogen atom or a methoxy;\n
R3 is selected from the group consisting of NR4R5, aryl, heteroaryl, alkenyl, an alkynyl, an alkoxyl, a cycloalkyl containing from 5 to 10 carbon atoms and containing eventually —CO—, —O—, —S—, —SO—, —SO2—, —CHOH— or —NR12—, or one of the radicals defined by the following structure:\n\n
wherein R4 and R5 taken together form a group consisting of a radical cycloalkyl containing from 3 to 10 carbon atoms and eventually interrupted with one or more hetero atoms or by —CO—, —SO—, —SO2—, —CHOH— or —NR14—;\n
R6 is selected from the group consisting of alkyl containing from 1 to 3carbon atoms;\n
R7 is selected from the group consisting of alkyl containing from 1 to 3 carbon atoms;\n
R6 and R7 taken together might form a cycloalkyl containing from 3 to 10 carbon atoms and eventually interrupted with one or more hetero atoms or by —CO—, —SO—, —SO2—, —CHOH— or —NR13—;\n
R8 is selected from the group consisting of hydrogen and alkyl from 1 to 3 carbon atoms;\n
R9 and R10 vary independently and are selected from the group consisting of methyl or a hydrogen;\n
R11 is selected from the group consisting of aryl, heteroaryl or an alkyl from 1 to 6 carbon atoms;\n
R12 is selected from the group consisting of hydrogen or alkyl containing from 1 to 3 carbon atoms;\n
R13 is selected from the group consisting of hydrogen or alkyl containing from 1 to 3 carbon atoms; and\n
R14 represents an alkyl containing from 1 to 3 carbon atoms."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["A compound or pharmaceutically acceptable salt thereof as recited in claim 1 wherein the compound is:"],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["A compound or pharmaceutically acceptable salt thereof as recited in claim 1 wherein the compound is:"],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["A compound or pharmaceutically acceptable salt thereof as recited in claim 3 wherein the compound is:"],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["A pharmaceutical composition comprising a therapeutically-effective amount of a compound, said compound selected from a family of compounds of claim 1, 2, or 3 or a pharmaceutically-acceptable salt thereof."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["A method of modulating a cannabinoid receptor comprising contacting the cannabinoid receptor with a compound recited in claim 1."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["A method of modulating a cannabinoid receptor comprising contacting the cannabinoid receptor with a compound recited in claim 2."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["A method of modulating a cannabinoid receptor comprising contacting the cannabinoid receptor with a compound recited in claim 3."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["A method of treating neuropathic pain in a subject, said method comprising administering to the subject having or susceptible to said pain or pain-associated disorder, a therapeutically-effective amount of a compound of claim 1, or a pharmaceutically-acceptable salt thereof."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["A method of treating neuropathic pain in a subject, said method comprising administering to the subject having or susceptible to said pain or pain-associated disorder, a therapeutically-effective amount of a compound of claim 2, or a pharmaceutically-acceptable salt thereof."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["A method of treating neuropathic pain in a subject, said method comprising administering to the subject having or susceptible to said pain or pain-associated disorder, a therapeutically-effective amount of a compound of claim 3, or a pharmaceutically-acceptable salt thereof."],"number":13,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}